Rifabutin
- Atc Codes:J04AB04
- CAS Codes:72559-06-9
- PHARMGKB ID:72559-06-9
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Induces
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Mycobutin; Belgium: Mycobutin; Czech Republic: Mycobutin; Denmark: Rifabutin; Finland: Ansatipin; France: Ansatipine; Germany: Alfacid, Mycobutin; Greece: Ansatipin, Ansatipine, Mycobutin; Ireland: Mycobutin; Italy: Mycobutin; Luxembourg: Mycobutin; Netherlands: Mycobutin; Portugal: Mycobutin; Romania: Mycobutin; Spain: Ansatipin; Sweden: Ansatipin; UK: Mycobutin.
North America
Canada: Mycobutin; USA: Mycobutin.
Drug combinations
Chemistry
Rifabutin: C~46~H~62~N~4~O~11~. Mw: 847.00. (9S,12E,14S,15R,16S,17R,18R,19R,20S,21S,22E,24Z)-6-16,18,20-Tetrahydroxy-1′-isobutyl-14-methoxy-7,9,15,17,19,21,25-heptamethylspiro[9,4-(epoxypentadeca[1,11,13]trienimino)-2H-furo[2′,3′:7,8]naphth[1,2-d]imidazole-2,4′-piperidine]-5,10,26(3H,9H)-trione,16-acetate. CAS-72559-06-9 (1993).
Pharmacologic Category
Antimycobacterials; Antituberculosis Agents. Miscellaneous Antibacterials; Rifamycins. (ATC-Code: J04AB04).
Mechanism of action
Inhibits DNA-dependent RNA polymerase at β subunit which prevents chain initiation.
Therapeutic use
Prevention of disseminated Mycobacterium avium complex in advanced HIV infection.
Pregnancy and lactiation implications
Use with caution during pregnancy and in nursing women.
Unlabeled use
Utilized in multidrug regimens for treatment of Mycobacterium avium complex.
Contraindications
Hypersensitivity to rifabutin, any other rifamycins, or any component of the formulation. Rifabutin contraindicated in WBC <1000/mm^3^ or platelet count <50000/mm^3^.
Warnings and precautions
Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea and pseudomembranous colitis. Use with caution in liver impairment (discontinue if AST >500 units/L or if total bilirubin is >3 mg/dL), and in renal impairment. As single agent, must not be administered with active tuberculosis since its use may lead to development of tuberculosis resistant to both rifabutin and rifampin.